Abstract
Two subtypes of the mammalian cannabinoid receptor have been identified and successfully cloned since 1990. The CB1 receptor is primarily located in the central nervous system and the CB2 receptor is almost exclusively expressed in cells of the immune system. The CB1 and CB2 receptors are both G-protein coupled receptors and are involved in the inhibition of adenylate cyclase. The CB2 receptor is of particular importance due to its involvement in signal transduction in the immune system, making it a potential target for therapeutic immune intervention. A number of these selective ligands are derivatives of traditional dibenzopyran based cannabinoids. These include the very recently synthesized (2R)- 1-methoxy-3-(2-methylbutyl)-Δ8-THC (JWH-359) which has a 224 fold selectivity for the CB2 receptor, readily comparable to the well known 1-deoxy-3-(1,1-dimethylbutyl)-Δ8-THC (JWH-133) which has 200 fold selectivity for the CB2 receptor. Several 9-hydroxyhexahydrocannabinols have also been synthesized and are found to be selective high affinity ligands for the CB2 receptor. These are 1-deoxy-9β-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, Ki = 2.7 nM) and 1-deoxy-9β-hydroxy-dimethylpentylhexahydrocannabinol (JWH-300, Ki = 5.3 nM). CB2 selective cannabimimetic indoles include 1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-[1-morpholine]ethyl)-5-methoxyindole (L768242), (R)-3- (2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole (AM1241) and 1-propyl-2-methyl-3-(1-naphthoyl) indole (JWH-015), which exhibit significant selectivity for the CB2 receptor coupled with weak affinity for the CB1 receptor. Bristol-Meyer Squibb has produced a phenylalanine derived cannabimimetic indole which possesses high CB2 affinity (Ki = 8 nM) and very low affinity for the CB1 receptor (Ki = 4000 nM). This review will discuss the current advances and recent results in the structure-activity relationships (SAR) of selective ligands for the cannabinoid CB2 receptor.
Keywords: Cannabinoids, structure-activity relationships, CB2 receptor, CB2 selective ligands, aminoalkylindoles
Current Topics in Medicinal Chemistry
Title: Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Volume: 8 Issue: 3
Author(s): John W. Huffman and Karla-Sue C. Marriott
Affiliation:
Keywords: Cannabinoids, structure-activity relationships, CB2 receptor, CB2 selective ligands, aminoalkylindoles
Abstract: Two subtypes of the mammalian cannabinoid receptor have been identified and successfully cloned since 1990. The CB1 receptor is primarily located in the central nervous system and the CB2 receptor is almost exclusively expressed in cells of the immune system. The CB1 and CB2 receptors are both G-protein coupled receptors and are involved in the inhibition of adenylate cyclase. The CB2 receptor is of particular importance due to its involvement in signal transduction in the immune system, making it a potential target for therapeutic immune intervention. A number of these selective ligands are derivatives of traditional dibenzopyran based cannabinoids. These include the very recently synthesized (2R)- 1-methoxy-3-(2-methylbutyl)-Δ8-THC (JWH-359) which has a 224 fold selectivity for the CB2 receptor, readily comparable to the well known 1-deoxy-3-(1,1-dimethylbutyl)-Δ8-THC (JWH-133) which has 200 fold selectivity for the CB2 receptor. Several 9-hydroxyhexahydrocannabinols have also been synthesized and are found to be selective high affinity ligands for the CB2 receptor. These are 1-deoxy-9β-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, Ki = 2.7 nM) and 1-deoxy-9β-hydroxy-dimethylpentylhexahydrocannabinol (JWH-300, Ki = 5.3 nM). CB2 selective cannabimimetic indoles include 1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-[1-morpholine]ethyl)-5-methoxyindole (L768242), (R)-3- (2-Iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H-indole (AM1241) and 1-propyl-2-methyl-3-(1-naphthoyl) indole (JWH-015), which exhibit significant selectivity for the CB2 receptor coupled with weak affinity for the CB1 receptor. Bristol-Meyer Squibb has produced a phenylalanine derived cannabimimetic indole which possesses high CB2 affinity (Ki = 8 nM) and very low affinity for the CB1 receptor (Ki = 4000 nM). This review will discuss the current advances and recent results in the structure-activity relationships (SAR) of selective ligands for the cannabinoid CB2 receptor.
Export Options
About this article
Cite this article as:
Huffman W. John and Marriott C. Karla-Sue, Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor, Current Topics in Medicinal Chemistry 2008; 8 (3) . https://dx.doi.org/10.2174/156802608783498014
DOI https://dx.doi.org/10.2174/156802608783498014 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Current Pharmaceutical Design Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Reduced Serotonin Transporter Levels and Inflammation in the Midbrain Raphe of 12 Month Old APP<sub>swe</sub>/PSEN<sub>1dE9</sub> Mice
Current Alzheimer Research Polymer-dendrimer Hybrids as Carriers of Anticancer Agents
Current Drug Targets Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets